A little more than a month after Bay Area-based Freenome snagged $300 million in a Series D financing round, the company scored an additional $290 million from an investment made by Swiss pharma giant Roche.
If you are not happy with the results below please do another search
50 search results for:
IPG Health Network announced that Franklin Williams joined the AREA 23 executive leadership team as EVP, director of experience design, reporting to chief creative officer Tim Hawkey.
Syneos Health released the biopharmaceutical solutions organization’s 12th annual Dealmakers’ Intentions Survey. Conducted on an annual basis, the survey provides a review of biopharmaceutical dealmakers’ expectations for deal activity, supply and demand for specific assets in different development stages, pitfalls leading to deal failure and other factors affecting dealmaking.
Shares in PharmaMar jumped almost 20 percent on January 11 after the Spanish drugmaker said lab trials suggested the company’s Plitidepsin drug was effective against the main COVID-19 variants, including the highly contagious Omicron.
California-based Dren Bio and Pfizer partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
The Omicron variant of COVID-19 is on track to infect more than half of Europeans, but it should not yet be seen as a flu-like endemic illness, the World Health Organization (WHO) said on Tuesday.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start with deal announcements and plans to drive biopharma companies through the year.
With record-shattering new cases of COVID-19 across the United States, the urgency for vaccinations is even greater than ever. In addition, Pfizer reported that an Omicron-specific vaccine will be available in March, should it be necessary.
A U.S. man with terminal heart disease was implanted with a genetically modified pig heart in a first-of-its-kind surgery, and three days later the patient is doing well, his doctors reported on January 10.
BioNTech said the German COVID-19 vaccine maker developed a method to quickly determine whether a new virus variant is a cause for concern, collaborating with British artificial intelligence startup InstaDeep Ltd.